Navigating India's Evolving Pharmaceutical Regulatory Landscape Regulatory Expertise Keep up with evolving requirements Licensing Support Secure and maintain approvals Market Access Strategy Navigate entry and reimbursement
CONTEXT The Regulatory Challenge Recent Developments GSR-327(E) dated 03.04.2017 introduced stringent requirements for Bioequivalence study submissions for BCS Class II and IV products before Manufacturing Licence grants. This regulatory shift has significantly impacted product permissions across the pharmaceutical sector. Non-compliance has resulted in suspension or withdrawal of product licences, creating urgent challenges for manufacturers and exporters. Industry Impact As highlighted in recent media coverage, "Pharma testing in overdrive as regulators intensify checks," regulatory authorities are taking a more proactive stance on compliance verification. Manufacturers face mounting pressure to demonstrate adherence whilst maintaining uninterrupted market access both domestically and internationally.
Understanding the Stakes The current regulatory environment demands unprecedented attention to compliance. Product permissions are no longer guaranteed without comprehensive documentation and robust scientific evidence. Licence Suspensions Immediate market withdrawal risks for non-compliant products, affecting revenue streams and market position Export Restrictions International market access compromised without proper regulatory documentation and BE study compliance Timeline Pressures Accelerated deadlines for submission of supporting data and regulatory responses to maintain operations
OUR SOLUTION GNH India Pharmaceuticals Limited We are a specialised regulatory affairs and pharmaceutical development consultancy dedicated to helping manufacturers navigate India's complex regulatory landscape with confidence. Our team combines deep regulatory expertise with scientific excellence, offering comprehensive solutions that address your most pressing compliance challenges whilst accelerating market access timelines. With proven experience supporting both Indian manufacturers and multinational pharmaceutical companies, we understand the unique pressures you face in maintaining regulatory compliance.
Our Core Services Comprehensive regulatory support designed to streamline compliance and restore product permissions
- CTD/eCTD Dossier Preparation Complete regulatory documentation services
- Stability Studies ICH-compliant testing programmes
- BA/BE Study Support End-to-end bioequivalence solutions
SERVICE 1 CTD/eCTD Dossier Preparation Comprehensive preparation of regulatory dossiers for submission to Indian and international authorities, ensuring completeness, accuracy, and alignment with current guidelines. What We Deliver Full Module 1-5 CTD compilation aligned with ICH guidelines Electronic Common Technical Document (eCTD) formatting for global submissions Quality, non-clinical, and clinical data compilation and review Regulatory gap analysis and deficiency responses Submission-ready documentation meeting CDSCO and international requirements Key Benefit: Our meticulous approach ensures first- time approval success rates whilst reducing review cycles and regulatory queries.
SERVICE 2 Stability Studies Conducting robust stability studies under ICH conditions to support shelf-life claims and regulatory approvals. Our stability programmes provide the scientific foundation for product lifecycle management. ICH-Compliant Protocols Long-term, intermediate, and accelerated stability studies following Q1A-Q1F guidelines for all climatic zones Photo-Stability Testing Comprehensive light exposure studies per ICH Q1B requirements for light- sensitive formulations Ongoing Monitoring Annual batch analysis programmes ensuring continued product quality throughout commercial lifecycle Regulatory Reporting Complete documentation packages with statistical analysis, trending, and submission-ready stability reports
SERVICE
- BA/BE Study Support Comprehensive Bioequivalence Solutions End-to-end assistance for Bioavailability (BA) and Bioequivalence (BE) studies, including protocol design, study management, data analysis, and submission-ready reporting to meet regulatory requirements. Our BE services are specifically designed to address GSR-327(E) mandates for BCS Class II and IV products, ensuring your submissions meet CDSCO expectations.
- Protocol Design Scientifically rigorous study designs compliant with CDSCO and international guidelines
- Study Management Complete oversight from site selection through volunteer recruitment and sample analysis
- Data Analysis Statistical evaluation using validated methodologies with bioequivalence determination
- Regulatory Reporting Comprehensive study reports ready for immediate regulatory submission
Why Partner With GNH India? Regulatory Expertise Deep understanding of CDSCO requirements and international regulatory frameworks, ensuring submissions meet evolving standards Accelerated Timelines Streamlined processes and efficient project management reduce time- to-approval whilst maintaining quality standards Risk Mitigation Proactive compliance strategies minimise regulatory queries, deficiencies, and potential product suspensions Global Perspective Experience with Indian and international markets enables comprehensive regulatory strategies for export products Tailored Solutions Customised approaches based on your specific portfolio, timelines, and compliance objectives rather than one-size-fits-all services Proven Track Record Successful submissions and restored product permissions for manufacturers across therapeutic categories
BENEFITS The Value We Deliver Partnering with GNH India provides tangible benefits that directly impact your business operations and market position. Restore Product Permissions Streamline the process of bringing suspended products back to market through compliant submissions and robust scientific documentation Maintain Market Access Ensure uninterrupted product availability in India whilst supporting export requirements for global markets Mitigate Regulatory Risks Proactive compliance strategies reduce the likelihood of future suspensions, queries, and regulatory actions
Our Proven Process 1Initial Assessment Comprehensive portfolio review and regulatory gap analysis to identify priority actions and compliance requirements
- Strategic Planning Customised roadmap development with timelines, resource allocation, and regulatory submission strategies 3Documentation Development Complete preparation of dossiers, study protocols, and supporting documentation to regulatory standards
- Study Execution Management of stability and BE studies with quality oversight and real-time progress monitoring 5Regulatory Submission Filing of complete applications with proactive regulator engagement and deficiency response management
- Approval & Beyond Post-approval support, ongoing compliance monitoring, and lifecycle management services
Success Metrics Our track record demonstrates the tangible impact of our regulatory support services 95% First-Time Approval Rate For CTD/eCTD submissions to CDSCO and international regulators 40% Timeline Reduction Average acceleration in approval timelines compared to industry standards 200+ Successful Submissions Regulatory dossiers approved across therapeutic categories and markets 50+ Active Partnerships Manufacturers and exporters currently supported across India
CASE STUDY Recent Success Story Challenge A mid-sized pharmaceutical manufacturer faced suspension of 12 product licences due to incomplete BE study documentation for BCS Class II products. The company risked significant revenue loss and export contract penalties. Our Solution We conducted a rapid portfolio assessment, prioritised products by commercial importance, and designed an accelerated compliance programme. Within six months, we completed BE studies for priority products, prepared comprehensive CTD dossiers, and submitted complete applications to CDSCO. Results 8 of 12 products restored to market within 9 months Export contracts preserved with international partners Remaining 4 products in final approval stages Ongoing partnership for portfolio maintenance Client Testimonial: "GNH India's expertise and efficiency were instrumental in recovering our market position. Their systematic approach transformed a crisis into an opportunity to strengthen our regulatory foundation."
NEXT STEPS Let's Discuss Your Needs We understand that every manufacturer faces unique challenges in the current regulatory environment. Our solutions are tailored to your specific portfolio, timelines, and compliance objectives.
- Schedule a Consultation Complimentary portfolio assessment and regulatory gap analysis
- Receive Your Custom Proposal Detailed recommendations with timelines and resource requirements
- Begin Your Compliance Journey Immediate project initiation with dedicated regulatory team support We would be delighted to schedule a call or meeting to discuss how our tailored solutions can specifically support your portfolio and compliance objectives.